Longboard Pharmaceuticals (LBPH) Stock Forecast, Price Target & Predictions
LBPH Stock Forecast
Longboard Pharmaceuticals stock forecast is as follows: an average price target of $50.50 (represents a 44.66% upside from LBPH’s last price of $34.91) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
LBPH Price Target
LBPH Analyst Ratings
Longboard Pharmaceuticals Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Sep 06, 2024 | Joel Beatty | Robert W. Baird | $60.00 | $33.89 | 77.04% | 71.87% |
Jul 01, 2024 | Josh Schimmer | Cantor Fitzgerald | $90.00 | $28.76 | 212.93% | 157.81% |
Jun 10, 2024 | Kalpit Patel | B.Riley Financial | $36.00 | $18.11 | 98.79% | 3.12% |
Apr 30, 2024 | Joel Beatty | Robert W. Baird | $36.00 | $21.30 | 69.01% | 3.12% |
Nov 11, 2022 | - | Guggenheim | $16.00 | $4.60 | 247.83% | -54.17% |
Longboard Pharmaceuticals Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | 1 | 3 | 4 |
Avg Price Target | $60.00 | $62.00 | $55.50 |
Last Closing Price | $34.91 | $34.91 | $34.91 |
Upside/Downside | 71.87% | 77.60% | 58.98% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Aug 05, 2024 | B. Riley | Buy | Buy | Hold |
Jul 02, 2024 | Citigroup | Buy | Buy | Hold |
Jul 01, 2024 | Cantor Fitzgerald | Overweight | Overweight | Hold |
Jun 11, 2024 | Citigroup | Buy | Buy | Hold |
May 03, 2024 | Wedbush | Outperform | Outperform | Hold |
Jan 16, 2024 | Cantor Fitzgerald | Overweight | Overweight | Hold |
Mar 09, 2023 | Citigroup | Buy | Buy | Hold |
Nov 11, 2022 | Guggenheim | Buy | Buy | Hold |
Longboard Pharmaceuticals Financial Forecast
Longboard Pharmaceuticals Revenue Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - |
Avg Forecast | - | - | - | - | - | $3.00M | - |
High Forecast | - | - | - | - | - | $3.00M | - |
Low Forecast | - | - | - | - | - | $3.00M | - |
# Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 |
Surprise % | - | - | - | - | - | - | - |
Longboard Pharmaceuticals EBITDA Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|
# Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 |
EBITDA | - | - | - | - | - | - | - |
Avg Forecast | - | - | - | - | - | - | - |
High Forecast | - | - | - | - | - | - | - |
Low Forecast | - | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - | - |
Longboard Pharmaceuticals Net Income Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|
# Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 |
Net Income | - | - | - | - | - | - | - |
Avg Forecast | $-25.25M | $-24.31M | $-24.59M | $-23.81M | $-23.05M | $-21.73M | $-17.13M |
High Forecast | $-25.25M | $-24.31M | $-24.59M | $-23.81M | $-23.05M | $-19.36M | $-17.13M |
Low Forecast | $-25.25M | $-24.31M | $-24.59M | $-23.81M | $-23.05M | $-24.10M | $-17.13M |
Surprise % | - | - | - | - | - | - | - |
Longboard Pharmaceuticals SG&A Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|
# Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 |
SG&A | - | - | - | - | - | - | - |
Avg Forecast | - | - | - | - | - | - | - |
High Forecast | - | - | - | - | - | - | - |
Low Forecast | - | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - | - |
Longboard Pharmaceuticals EPS Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|
# Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 |
EPS | - | - | - | - | - | - | - |
Avg Forecast | $-0.65 | $-0.63 | $-0.63 | $-0.61 | $-0.59 | $-0.56 | $-0.44 |
High Forecast | $-0.65 | $-0.63 | $-0.63 | $-0.61 | $-0.59 | $-0.50 | $-0.44 |
Low Forecast | $-0.65 | $-0.63 | $-0.63 | $-0.61 | $-0.59 | $-0.62 | $-0.44 |
Surprise % | - | - | - | - | - | - | - |
Longboard Pharmaceuticals Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
SNSE | Sensei Biotherapeutics | $0.61 | $5.50 | 801.64% | Buy |
HOWL | Werewolf Therapeutics | $2.02 | $12.00 | 494.06% | Buy |
MOLN | Molecular Partners | $5.51 | $29.00 | 426.32% | Buy |
ANEB | Anebulo Pharmaceuticals | $1.80 | $6.00 | 233.33% | Buy |
EWTX | Edgewise Therapeutics | $17.52 | $48.00 | 173.97% | Buy |
NUVB | Nuvation Bio | $2.79 | $7.00 | 150.90% | Buy |
STOK | Stoke Therapeutics | $14.70 | $33.33 | 126.73% | Buy |
NXTC | NextCure | $1.42 | $3.00 | 111.27% | Buy |
CCCC | C4 Therapeutics | $5.40 | $11.33 | 109.81% | Hold |
CELC | Celcuity | $15.06 | $31.50 | 109.16% | Buy |
DSGN | Design Therapeutics | $4.67 | $9.67 | 107.07% | Buy |
LBPH | Longboard Pharmaceuticals | $34.86 | $50.50 | 44.87% | Buy |
GRPH | LENZ Therapeutics | $3.18 | $4.00 | 25.79% | Hold |
IKNA | Ikena Oncology | $1.69 | $1.33 | -21.30% | Buy |
CYT | Cyteir Therapeutics | $3.02 | $2.00 | -33.77% | Sell |
TIL | Instil Bio | $14.25 | $6.50 | -54.39% | Hold |
LBPH Forecast FAQ
Is Longboard Pharmaceuticals a good buy?
Yes, according to 5 Wall Street analysts, Longboard Pharmaceuticals (LBPH) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 5 'Buy' recommendations, accounting for 100.00% of LBPH's total ratings.
What is LBPH's price target?
Longboard Pharmaceuticals (LBPH) average price target is $50.5 with a range of $16 to $90, implying a 44.66% from its last price of $34.91. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Longboard Pharmaceuticals stock go up soon?
According to Wall Street analysts' prediction for LBPH stock, the company can go up by 44.66% (from the last price of $34.91 to the average price target of $50.5), up by 157.81% based on the highest stock price target, and down by -54.17% based on the lowest stock price target.
Can Longboard Pharmaceuticals stock reach $50?
LBPH's average twelve months analyst stock price target of $50.5 supports the claim that Longboard Pharmaceuticals can reach $50 in the near future.
What is Longboard Pharmaceuticals's current price target trend?
1 Wall Street analyst forecast a $60 price target for Longboard Pharmaceuticals (LBPH) this month, up 71.87% from its last price of $34.91. Compared to the last 3 and 12 months, the average price target increased by 77.60% and increased by 58.98%, respectively.
What are Longboard Pharmaceuticals's analysts' financial forecasts?
Longboard Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $3M (high $3M, low $3M), average EBITDA is $0 (high $0, low $0), average net income is $-61.91M (high $-59.539M, low $-64.28M), average SG&A $0 (high $0, low $0), and average EPS is $-1.592 (high $-1.531, low $-1.653). LBPH's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-97.957M (high $-97.957M, low $-97.957M), average SG&A $0 (high $0, low $0), and average EPS is $-2.519 (high $-2.519, low $-2.519).